NO2017018I2 - umeklidiniumbromid - Google Patents

umeklidiniumbromid

Info

Publication number
NO2017018I2
NO2017018I2 NO2017018C NO2017018C NO2017018I2 NO 2017018 I2 NO2017018 I2 NO 2017018I2 NO 2017018 C NO2017018 C NO 2017018C NO 2017018 C NO2017018 C NO 2017018C NO 2017018 I2 NO2017018 I2 NO 2017018I2
Authority
NO
Norway
Prior art keywords
umeklidiniumbromid
Prior art date
Application number
NO2017018C
Other languages
English (en)
Other versions
NO2017018I1 (no
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO2017018I1 publication Critical patent/NO2017018I1/no
Publication of NO2017018I2 publication Critical patent/NO2017018I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO2017018C 2004-04-27 2017-05-04 umeklidiniumbromid NO2017018I2 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27
PCT/US2005/014386 WO2005104745A2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists

Publications (2)

Publication Number Publication Date
NO2017018I1 NO2017018I1 (no) 2017-05-04
NO2017018I2 true NO2017018I2 (no) 2018-05-14

Family

ID=35242158

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20065417A NO338959B1 (no) 2004-04-27 2006-11-24 Muskariniske acetylkolinreceptorantagonister, farmasøytiske preparater samt slike forbindelser for anvendelse.
NO2017018C NO2017018I2 (no) 2004-04-27 2017-05-04 umeklidiniumbromid
NO2017017C NO2017017I1 (no) 2004-04-27 2017-05-04 umeklinidium og vilanterol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20065417A NO338959B1 (no) 2004-04-27 2006-11-24 Muskariniske acetylkolinreceptorantagonister, farmasøytiske preparater samt slike forbindelser for anvendelse.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2017017C NO2017017I1 (no) 2004-04-27 2017-05-04 umeklinidium og vilanterol

Country Status (37)

Country Link
US (9) US7498440B2 (no)
EP (3) EP3111936A1 (no)
JP (2) JP5014121B2 (no)
KR (2) KR101037026B1 (no)
CN (2) CN102040602A (no)
AP (1) AP2213A (no)
AR (1) AR050902A1 (no)
AU (1) AU2005237576B2 (no)
BR (1) BRPI0510170B8 (no)
CA (2) CA2564742C (no)
CY (3) CY1113196T1 (no)
DK (2) DK1740177T3 (no)
EA (2) EA021994B1 (no)
EC (1) ECSP066940A (no)
ES (2) ES2600405T3 (no)
HK (1) HK1102423A1 (no)
HR (2) HRP20120832T1 (no)
HU (2) HUE031304T2 (no)
IL (1) IL178152A (no)
LT (1) LT2570128T (no)
LU (1) LU92565I2 (no)
MA (1) MA28631B1 (no)
MX (1) MXPA06012405A (no)
MY (1) MY144753A (no)
NL (1) NL300694I2 (no)
NO (3) NO338959B1 (no)
NZ (1) NZ549997A (no)
PE (1) PE20060259A1 (no)
PL (2) PL2570128T3 (no)
PT (2) PT1740177E (no)
SG (1) SG186597A1 (no)
SI (2) SI2570128T1 (no)
TW (1) TWI363759B (no)
UA (1) UA95768C2 (no)
UY (1) UY28871A1 (no)
WO (1) WO2005104745A2 (no)
ZA (1) ZA200608565B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
MXPA06004242A (es) * 2003-10-17 2006-06-28 Glaxo Group Ltd Antagonistas del receptor muscarinico de la acetilcolina.
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
US20070185148A1 (en) * 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
EP1725564A4 (en) * 2004-03-17 2007-09-12 Glaxo Group Ltd ANTAGONISTS OF THE M3 MUSCARIN ACETYL CHOLIN RECEPTOR
US20080194619A1 (en) * 2004-04-05 2008-08-14 Laurent Lecanu Anti-Hiv Quinuclidine Compounds
MY144753A (en) 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) * 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
WO2006055553A2 (en) * 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
WO2007022351A2 (en) * 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
MX2008013411A (es) 2006-04-20 2008-11-04 Glaxo Group Ltd Nuevos compuestos.
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
US8003663B2 (en) 2006-08-01 2011-08-23 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
TW200946525A (en) 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
TW201000476A (en) 2008-02-06 2010-01-01 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
EP2400950B1 (en) 2009-02-26 2019-05-22 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
CA2759476C (en) 2009-04-30 2018-10-09 Julie Nicole Hamblin Novel compounds
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
JP2013512878A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド 新規化合物
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
CN102947309B (zh) * 2010-01-28 2016-02-10 西伦制药公司 7-氮*双环[2.2.1]庚烷衍生物、其制备方法、及其制可药用途
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
JP2013529606A (ja) * 2010-06-22 2013-07-22 シエシー ファルマセウティチィ ソシエタ ペル アチオニ 抗ムスカリン薬含有乾燥粉末配合物
DK2614058T3 (en) 2010-09-08 2015-09-28 Glaxosmithkline Ip Dev Ltd Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide.
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
CA2838030A1 (en) * 2011-06-08 2012-12-13 Glaxo Group Limited Combination comprising umeclidinium and a corticosteroid
EP2717867A1 (en) 2011-06-08 2014-04-16 Glaxo Group Limited Dry powder inhaler compositions comprising umeclidinium
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
CN104619706B (zh) * 2012-08-15 2017-06-20 葛兰素集团有限公司 化学方法
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
CA2921621C (en) * 2013-07-13 2018-08-28 Beijing Fswelcome Technology Development Co., Ltd Quinine compounds, and optical isomers, preparation method and medical use thereof
KR20160034920A (ko) 2013-07-30 2016-03-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 과도한 발한의 치료를 위한 국소 조성물 및 그의 사용 방법
JP6475707B2 (ja) 2013-10-17 2019-02-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 呼吸器疾患の治療のためのｐｉ３ｋ阻害剤
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
EA201692111A1 (ru) 2014-05-12 2017-08-31 Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
US10987363B2 (en) 2014-05-28 2021-04-27 Glaxosmithkline Intellectual Property Development Limited Fluticasone furoate in the treatment of COPD
ES2751698T3 (es) 2014-11-03 2020-04-01 Olon Spa Procedimiento para la preparación del éster etílico del ácido 1-(2-halogen-etil)-4-piperidina-carboxílico
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
PT109740B (pt) 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
JP2023523453A (ja) * 2020-04-26 2023-06-05 ベイジン・ショウバイ・ファーマシューティカル・カンパニー・リミテッド Ｍ受容体拮抗剤の結晶体、調製方法及びその応用
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440A (pt) 2021-09-03 2023-03-03 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) * 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (no) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
NL192564C (nl) 1982-10-08 1997-10-03 Glaxo Group Ltd Inrichting voor het toedienen van medicamenten aan patiënten.
PT83094B (pt) 1985-07-30 1993-07-30 Glaxo Group Ltd Dispositivos proprios para a administracao de medicamentos a pacientes
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) * 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
EP0944626A4 (en) * 1996-12-02 2002-09-04 Univ Georgetown TROPANE DERIVATIVES AND SYNTHESIS METHOD
US6248752B1 (en) * 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1353919B1 (en) * 2000-12-28 2006-07-26 Almirall Prodesfarma AG Novel quinuclidine derivatives and medicinal compositions containing the same
EP1438309A1 (en) * 2001-10-17 2004-07-21 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
BR0214016A (pt) * 2001-11-09 2004-10-13 Upjohn Co Compostos azabicìclico-fenil-fundido heterocìclicos e seu uso como ligandos alfa 7 nachr
IL162596A0 (en) * 2001-12-20 2005-11-20 S A L V A T Lab Sa 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists
US6696462B2 (en) * 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
US7232841B2 (en) 2003-04-07 2007-06-19 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
TW200519109A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AR045913A1 (es) 2003-07-17 2005-11-16 Glaxo Group Ltd Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
MY143366A (en) 2003-10-14 2011-04-29 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
MXPA06004242A (es) 2003-10-17 2006-06-28 Glaxo Group Ltd Antagonistas del receptor muscarinico de la acetilcolina.
TW200524577A (en) 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
UY28645A1 (es) 2003-12-03 2005-06-30 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
UY28646A1 (es) 2003-12-03 2005-06-30 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US20090253908A1 (en) 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
JP2007530451A (ja) 2004-03-11 2007-11-01 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US20070185148A1 (en) 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
JP2007529514A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1725240A4 (en) 2004-03-17 2009-03-25 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
EP1725564A4 (en) 2004-03-17 2007-09-12 Glaxo Group Ltd ANTAGONISTS OF THE M3 MUSCARIN ACETYL CHOLIN RECEPTOR
EP1732923A2 (en) 2004-04-07 2006-12-20 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
MY144753A (en) 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
WO2005118594A1 (en) 2004-05-28 2005-12-15 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
WO2006005057A2 (en) 2004-06-30 2006-01-12 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
JP2008509159A (ja) 2004-08-05 2008-03-27 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体拮抗薬
JP2008509158A (ja) 2004-08-06 2008-03-27 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
US20090258858A1 (en) 2004-10-29 2009-10-15 Jakob Busch-Petersen Muscarinic acetylcholine receptor antagonists
EP1827439A4 (en) 2004-11-15 2009-11-18 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
WO2006055553A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
JP2009503101A (ja) 2005-08-02 2009-01-29 グラクソ グループ リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1937267A4 (en) 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
WO2007022351A2 (en) 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
US7488827B2 (en) 2009-02-10
EA021994B1 (ru) 2015-10-30
EA201100019A1 (ru) 2011-12-30
NZ549997A (en) 2010-10-29
EP1740177A4 (en) 2010-05-05
US20160002220A1 (en) 2016-01-07
SG186597A1 (en) 2013-01-30
US20130030015A1 (en) 2013-01-31
KR20110010841A (ko) 2011-02-07
LU92565I2 (fr) 2014-12-02
EP2570128B1 (en) 2016-08-10
BRPI0510170B1 (pt) 2018-12-18
NO20065417L (no) 2006-12-29
CY2014043I1 (el) 2015-12-09
EA015033B1 (ru) 2011-04-29
CY1113196T1 (el) 2015-12-09
US8853404B2 (en) 2014-10-07
NO2017018I1 (no) 2017-05-04
JP5398871B2 (ja) 2014-01-29
KR101152032B1 (ko) 2012-06-11
CA2564742C (en) 2012-01-10
EP2570128A1 (en) 2013-03-20
TWI363759B (en) 2012-05-11
UA95768C2 (ru) 2011-09-12
HK1102423A1 (en) 2007-11-23
NO2017017I1 (no) 2017-05-04
ZA200608565B (en) 2019-12-18
HRP20120832T1 (hr) 2012-11-30
CN102040602A (zh) 2011-05-04
NO338959B1 (no) 2016-11-07
US8575347B2 (en) 2013-11-05
HRP20161385T1 (hr) 2016-12-02
JP5014121B2 (ja) 2012-08-29
US9045469B2 (en) 2015-06-02
AP2006003746A0 (en) 2006-10-31
US8183257B2 (en) 2012-05-22
US7498440B2 (en) 2009-03-03
BRPI0510170B8 (pt) 2021-05-25
US20120157491A1 (en) 2012-06-21
SI1740177T1 (sl) 2012-12-31
SI2570128T1 (sl) 2016-11-30
US20140371264A1 (en) 2014-12-18
AU2005237576A1 (en) 2005-11-10
AR050902A1 (es) 2006-12-06
AP2213A (en) 2011-03-01
DK2570128T3 (en) 2016-11-07
HUE031304T2 (hu) 2017-07-28
CA2755954A1 (en) 2005-11-10
US8309572B2 (en) 2012-11-13
US20150238470A1 (en) 2015-08-27
EP1740177A2 (en) 2007-01-10
IL178152A0 (en) 2006-12-31
TW200605887A (en) 2006-02-16
ECSP066940A (es) 2006-12-20
ES2600405T3 (es) 2017-02-08
HUS1400053I1 (hu) 2017-07-28
JP2012162559A (ja) 2012-08-30
UY28871A1 (es) 2005-11-30
BRPI0510170A (pt) 2007-10-02
PL2570128T3 (pl) 2017-09-29
CA2564742A1 (en) 2005-11-10
IL178152A (en) 2011-05-31
WO2005104745A3 (en) 2006-08-03
CY2014043I2 (el) 2015-12-09
WO2005104745A2 (en) 2005-11-10
NL300694I1 (no) 2015-12-29
PE20060259A1 (es) 2006-03-25
MXPA06012405A (es) 2007-01-17
EP1740177B1 (en) 2012-08-08
PT2570128T (pt) 2016-10-07
EA200601991A1 (ru) 2007-02-27
US20070185155A1 (en) 2007-08-09
KR20070015412A (ko) 2007-02-02
JP2007534769A (ja) 2007-11-29
EP3111936A1 (en) 2017-01-04
CN1976701A (zh) 2007-06-06
LU92565I9 (no) 2019-01-17
PT1740177E (pt) 2012-11-02
US20090124653A1 (en) 2009-05-14
MA28631B1 (fr) 2007-06-01
MY144753A (en) 2011-10-31
LT2570128T (lt) 2016-10-10
KR101037026B1 (ko) 2011-05-25
ES2392848T4 (es) 2014-10-01
AU2005237576B2 (en) 2012-01-12
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
CA2755954C (en) 2014-02-18
PL1740177T3 (pl) 2012-12-31
CY1118082T1 (el) 2017-06-28
ES2392848T3 (es) 2012-12-14
DK1740177T3 (da) 2012-10-29
US9144571B2 (en) 2015-09-29
NL300694I2 (no) 2015-12-29

Similar Documents

Publication Publication Date Title
CY2019034I2 (el) 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
NO2017018I2 (no) umeklidiniumbromid
DE502005005116D1 (de) Wischblatt
DE502005005035D1 (de) Wischblatt
DE502005005628D1 (de) Wischblatt
DE112005001624A5 (de) Brillengestell
ATE520680T1 (de) Hiv-hemmende 5-heterocyclylpyrimidine
ATE392425T1 (de) Thiazolyl-dihydro-indazole
DE502005004843D1 (de) Einspritzventil
ATE459633T1 (de) Makrolide
DE502005006395D1 (de) Verschlusskappe
DE502005005991D1 (de) Sensorleuchte
DE502005004842D1 (de) Wischblatt
DE112005000809A5 (de) Wankstabilisierungseinrichtung
DE502005008587D1 (de) Kugelgelenk
DE502005007739D1 (de) Kranballastierungssystem
DE502005007584D1 (de) Raftfahrzeuge
DE502005002602D1 (de) Fahrzeugtemperiersystem
DE502005004695D1 (de) Sicherheitsfangseil
DE502005007997D1 (de) Aftfahrzeug
AT500198B8 (de) Ladewagen
DE202004017327U1 (de) Fitnessrad
ATE389633T1 (de) Omega-phenyloctanamide
DE112005000794T5 (de) Urethanspritzpistolenanordnung
DE502005007686D1 (de) Gutverteileinrichtung